- No file added yet -

Supplementary material: Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/ her2-negative breast cancer

figure

posted on 2021-04-20, 09:34 authored by Junyan Wu, Wei Jiang, Zhichao He, Tian Zhang, Chongchong Guo, Jianli Zhao, Jianhong Zhu, Xiaoxia Yu, Chuxiong Chen, Jianfang Li, Jie JiangJie Jiang

Table S1．Model parameters for progression-free survival and overall survival.

Figure S1. Weibull plots of progression-free survival (PFS) and overall survival (OS) of all population. (A) PFS curves of ribociclib plus fulvestrant (B) PFS curves of fulvestrant (C) OS curves of ribociclib plus fulvestrant (D) OS curves of fulvestrant.

Figure S2. Weibull plots of progression-free survival (PFS) and overall survival (OS) of patients receiving first-Line treatment. (A) PFS curves of ribociclib plus fulvestrant (B) PFS curves of fulvestrant (C) OS curves of ribociclib plus fulvestrant (D) OS curves of fulvestrant.

Figure S3. Weibull plots of progression-free survival (PFS) and overall survival (OS) of patients receiving first-Line treatment. (A) PFS curves of ribociclib plus fulvestrant (B) PFS curves of fulvestrant (C) OS curves of ribociclib plus fulvestrant (D) OS curves of fulvestrant.